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Abstract
Functional neuroimaging and modern multivariate analysis techniques have greatly
contributed to research into the pathophysiology, diagnosis, and new treatments of
neurodegenerative diseases, such as Parkinson’s disease (PD). The pathogenesis of PD
symptoms, especially akinesia and rigidity, is associated with abnormalities of cortico-
striato-pallido-thalamocortical circuits. Although a resting tremor is one of the cardinal
features of PD, the pathophysiology underlying this symptom is unclear and is thought
to differ from those of akinesia and rigidity. The application of network analyses to
metabolic positron emission tomography scans of patients with PD has provided valuable
information concerning functional neural connectivity and identified the patterns of
covariance that are specific to the motor manifestations and many nonmotor features of
the disease, such as cognitive dysfunction. Functional imaging methods have revealed
PD-specific  brain  activation patterns,  including a  parkinsonian tremor-related net‐
work. Network-based algorithms might aid in the clinical diagnosis of patients with PD
from early symptoms and provide objective evidence of treatment responses.
Keywords: parkinson’s disease, tremor, metabolic brain networks, positron emission
tomography, deep brain stimulation
1. Introduction
A resting tremor, which results from a striatal dopamine (DA) deficiency, is one of the most
common motor symptoms of Parkinson’s disease (PD). A tremor-dominant type of PD is
exhibited by 36 to 49% of patients with PD [1]. Clinical and pathophysiological studies have
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revealed that the PD tremor has distinct characteristics compared with other major parkinso‐
nian signs, such as akinesia (bradykinesia) and rigidity [2, 3]. Studies that used the Unified
Parkinson’s Disease Rating Scale (UPDRS) have shown that the severity of patients’ akinesia
and rigidity symptoms correlates with the severity of striatal DA loss and the clinical progres‐
sion of the disease, while the severity of their tremor did not [4–7]. Although levodopa therapy
is still the gold standard in the treatment of PD, it is more effective on akinesia and rigidity
symptoms than it is on tremor. Furthermore, patients with the tremor-dominant type of PD
have a better prognosis compared to those with the akinesia-rigid type [8]. The thalamic ventral
intermediate  (Vim) nucleus is  considered the optimal  target  for  stereotactic  intervention
treatments of PD tremor. Indeed, ablation or deep brain stimulation (DBS) of the Vim nucleus
effectively reduces PD tremor while it does not improve akinesia or rigidity.
To date, metabolic changes in the brain networks of patients with PD have been analyzed with
a variety of neuroimaging techniques, including positron emission tomography (PET), single-
photon emission computed tomography (SPECT), and functional magnetic resonance
imaging (fMRI). Eidelberg and colleagues have applied multivariate analyses to [18F]fluoro‐
deoxyglucose (FDG)-PET scans in their studies of the brain networks of patients with PD, and
they found a PD-related pattern (PDRP) of spatial covariance. They showed that patients with
PD exhibit increased metabolism in the thalamus, globus pallidus, pons, and primary motor
cortex and decreased metabolism in the lateral premotor cortex, supplementary motor area
(SMA), and parietal association area. Interestingly, the scores for the PDRP expression of the
individual patients with PD correlated with their UPDRS motor subscores for akinesia and
rigidity, but not with their subscores for tremor. These findings suggested that PD tremors
might be associated with different patterns of activation in these regions compared to those
observed in the PDRP. Mure et al. (2011) identified a discrete PD-related tremor pattern
(PDTP) in the FDG-PET scans of a cohort of patients with tremor-dominant PD who had
undergone DBS in the thalamic Vim nucleus. They analyzed the scans that were obtained when
the patients were on- and off-stimulation with an Ordinal Trends/Canonical Variates Analysis,
which is a within-subject, network-mapping, and algorithm-guided principal component
analysis (PCA) method. They found that the PDTP topography was characterized by in‐
creased metabolism in the cerebellar dentate nucleus and primary cortex and, to a lesser
degree, in the putamen. In contrast to the PDRP, the scores for the PDTP expression correlat‐
ed with the tremor amplitudes and UPDRS motor scores for tremor, but not with the UPDRS
motor scores for akinesia and rigidity. In addition, the PDTP was modulated more by Vim-
DBS than by subthalamic DBS. Thus, these findings suggested that PD tremors might be
mediated by a distinct metabolic network that primarily involves cerebello-thalamo-cortical
pathways.
In this chapter, we introduce the recent advancements that have been made in neuroimag‐
ing research for elucidating the pathogenesis of PD tremor and other PD symptoms. In
addition, we emphasize the importance of quantitative analyses of the PDTP and PDRP in the
development of objective methods for precisely diagnosing PD and evaluating the effects of
treatments on PD tremor.
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2. Functional neuroimaging techniques: a brief overview
Functional neuroimaging is used in studies with the goal of elucidating the pathophysiology
of neurological disorders. Representative functional neuroimaging techniques are fMRI,
SPECT, and PET. The fMRI technique, which is employed more because injections of radio‐
tracers are not required, measures changes in the relative amounts of deoxyhemoglobin in
different regions of the brain. The interactions of deoxyhemoglobin with the water mole‐
cules surrounding blood vessels result in proton signals that produce blood-oxygenation-
level-dependent (BOLD) contrast in the scans. Increases in regional blood flow result in relative
decreases in deoxyhemoglobin and an increase in the BOLD signals. When neurons are active,
the supply of oxygenated blood to the active region increases [9]. Thus, increases in BOLD
signals are associated with local neuronal activity [9]. However, in contrast to imaging with
radiotracers, fMRI has a poor signal-to-noise ratio, and its signals are difficult to quantify.
Radiotracer imaging techniques, such as PET and SPECT, are used to investigate the pat‐
terns of cerebral glucose metabolism, cerebral blood flow, and specific neurochemical systems.
In general, even though SPECT imaging is less expensive and more widely available com‐
pared with PET imaging, PET has better spatial resolution and sensitivity. The most widely
used PET radiotracer is FDG. Because FDG uptake reflects cerebral glucose metabolism, it is
thought to measure regional synaptic activity [10]. [15O]-labeled water (H215O) PET can be used
to quantify regional cerebral blood flow (rCBF). As described above, increases in rCBF are
thought to reflect neuronal activity increases [9]. DAergic function can be evaluated by
measuring the storage capability of presynaptic DA with [18F]-fluorodopa or presynaptic DA
transporter binding with [123I]-iodine-123-beta-carbomethoxy-3 beta-(4-iodophenyltropane)
(CIT) and [18F]-fluoropropyl CIT. Postsynaptic DA receptors can also be assessed with [11C]-
raclopride [11]. Given the prominent role of nigrostriatal pathology in PD, radioligand imaging
of the DA system has been widely used in investigations of PD. However, many other
neurochemical systems, such as the serotonergic, adrenergic, and cholinergic systems, can be
examined with PET and SPECT imaging [12]. Because rCBF and cerebral metabolisms are
affected in many neurodegenerative disorders, PET and SPECT imaging techniques have
greatly contributed to the understanding of the abnormal brain circuitry underlying the
pathophysiology of PD.
3. Metabolic network mapping
Network analyses of functional brain imaging data are an innovative approach for examin‐
ing circuit abnormalities in neurodegenerative diseases. PD is related to the degeneration of
nigral DAergic neurons, which also alters activity in the thalamus, pallidum, and cortex. These
metabolic changes can be evaluated at the regional voxel level with standard univariate
approaches, such as statistical parametric mapping [13]. Disease-related abnormalities in brain
functional organization can also be assessed at the network level with multivariate analyti‐
cal procedures. The Scaled Subprofile Model (SSM) is an innovative multivariate approach
that is used to identify disease-specific brain networks [14]. SSM is a spatial covariance method
that is based on a PCA and that is used to assess the subject-by-region effects in functional
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brain images [15, 16]. The details of this method have been reviewed elsewhere [15–17]. Briefly,
the SSM is applied to multivoxel metabolic imaging data in a combined sample of scans from
healthy subjects and patients. Once a pattern is identified that distinguishes one group from
the other, its expression can be prospectively quantified on an individual basis [18, 19], and
the resulting subject scores can be correlated with clinical and physiological measures of
interest. The SSM/PCA and related multivariate techniques are well suited to the study of
circuit disorders, which are neurological diseases with stereotyped disturbances in brain
network organization. Resting state measures of regional glucose utilization provide an index
of local synaptic activity as well as of the biochemical maintenance processes that dominate
this condition. The effects of pathology on these functions have a greater influence on regional
cerebral metabolism and blood flow than physiological and/or hemodynamic factors do. It
was recognized early in imaging research that neurodegenerative processes are associated
with disease-specific alterations in functional connectivity across the whole brain. Therefore,
network approaches have increasingly been used to analyze the metabolic imaging data from
subjects with brain disorders, and these data have had a growing impact on imaging neuro‐
science.
4. Metabolic brain networks in PD
4.1. The PDRP
Presynaptic nigrostriatal DA loss is associated with abnormalities of the cortico-striato-pallido-
thalamocortical (CSPTC) loops. Applications of the SSM/PCA method to resting-state FDG-
PET scans of patients with PD have consistently revealed an abnormal disease-related spatial
covariance pattern in the CSPTC loops and related pathways [15, 20, 21]. This PDRP is
characterized by increased pallido-thalamic and pontine metabolism that is associated with
relative reductions in the premotor cortex, SMA, and parietal association cortices (Figure 1a).
The presence of the PDRP has been verified by its reproducibility in another independent PD
cohort [22], and it has been associated with standardized motor ratings in multiple patient
cohorts (Figure 1b) [23–25]. In general, PDRP expression has been found to correlate with
clinical ratings of akinesia and rigidity, but not with tremor ratings. Interestingly, longitudi‐
nal increases in the pattern of expression correlate with progression in the motor disability
ratings and concurrent PET measurements of presynaptic nigrostriatal DA function [26, 27].
In addition, the clinical outcomes of individual patients are associated with the degree of PDRP
expression that is observed during subthalamic nucleus (STN)-targeted surgical interven‐
tions, including ablation therapy and DBS. Moreover, in patients with untreated PD, the PDRP
expression scores that are determined with measures of cerebral perfusion in radiotracer
imaging, such as H215O-PET and 99mTc-ethyl cysteinate dimer SPECT, closely correlate with
the corresponding network values that are computed from scans of cerebral glucose metabo‐
lism (i.e., FDG-PET) from the same cohort [22, 28]. Thus, PDRP expression can be measured
in rCBF scans that are obtained by PET, SPECT, or perfusion-weighted MRI methods, such as
the arterial spin labeling technique [29, 30].
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Figure 1. Neuroimaging analysis on Parkinson’s disease-related pattern. (a) Parkinson’s disease (PD)-related pattern
(PDRP). This spatial covariance pattern of motor-related metabolism was identified by a multivariate analysis of
[18F]fluorodeoxyglucose (FDG)-positron emission tomography (PET) scans from 33 patients with PD and 33 age-match‐
ed normal control subjects. This pattern is characterized by hypermetabolism (red) in the thalamus, globus pallidus
(GP)/putamen (Put), pons, and primary motor cortex and relative metabolic reductions (blue) in the lateral premotor
(PMC) and posterior parietal cortex. (b) The scores of the PDRP expression in the subjects correlated with the motor
subscale scores on the Unified Parkinson’s Disease Rating Scale (UPDRS) from a combination of patients with PD from
three independent cohorts (n = 65; r = 0.68; p < 0.001) [6, 23, 25]. (From Eidelberg D. Metabolic brain networks in neuro‐
degenerative disorders: a functional imaging approach. Trends Neurosci. 2009;32:548-557, with permission from Elsevi‐
er).
4.2. The PD-related cognitive pattern (PDCP)
Although PD is clinically defined by its motor features, nonmotor symptoms that involve
cognitive dysfunction can appear, even in early clinical stages [31]. Mild cognitive impair‐
ment (MCI) in early PD typically involves visuomotor processing, working memory, and/or
aspects of executive performance [32, 33]. A FDG-PET study revealed decreased glucose
metabolism in the frontal and occipital cortices of patients with PD with and without appa‐
rent cognitive impairments [34]. After applying a SSM/PCA analysis to FDG-PET data from a
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cohort of PD patients without dementia, Huang et al. identified a significant pattern of
covariance that was related to cognitive performance [35]. This pattern, which was termed the
PDCP, is characterized by metabolic decreases in the rostral SMA (pre-SMA), precuneus, and
posterior parietal and prefrontal regions and increases in the dentate nucleus and cerebellar
cortex (Figure 2a). The expression of PDCP in nondemented patients with PD correlates with
the patients’ ratings on neuropsychological tests of memory and executive functioning (Figure
2b). In addition, PDCP expression shows stepwise increases in accordance with worsening
cognitive impairments (Figure 2c). In contrast to PDRP, the expression of PDCP is not
modulated by antiparkinsonian motor symptom treatments, such as levodopa and DBS.
Importantly, although both the PDRP and the PDCP increase in accordance with symptom
duration, the rate of the increase in PDCP expression was slower than that of PDRP in the same
subjects. These findings suggest that different neural systems underlie these two disease-
related metabolic networks.
Figure 2. Neuroimaging analysis on Parkinson’s disease-related cognitive pattern. (a) The PD-related cognitive pat‐
tern (PDCP). This spatial covariance pattern of cognition-related metabolism was identified by a network analysis of
FDG-PET scans from 15 patients with nondemented PD [35]. This pattern is characterized by hypometabolism (blue) of
the dorsolateral prefrontal cortex (PMC), rostral supplementary motor area (preSMA), precuneus, and posterior parie‐
tal regions and relative metabolic increases (red) in the dentate nucleus (DN) and cerebellar cortex. (b) The expression
of PDCP correlates with the performances on neuropsychological tests of memory and executive functioning (r = −0.67,
p < 0.001) of 56 patients with nondemented PD from two prospective validation groups and the original validation
group [35]. (c) Bar graph of PDCP expression [mean ± standard error of the mean (SE)] in patients with PD with de‐
mentia (PDD), multiple-domain mild cognitive impairment [MCI(m)], single-domain mild cognitive impairment
[MCI(s)], patients with PD without mild cognitive impairment [MCI(−)], and normal subjects. PDCP expression dif‐
fered significantly across the patient and control groups and among the PD groups. The asterisks indicate significant
increases in PDCP expression compared to normal controls. (From Eidelberg D. Metabolic brain networks in neurode‐
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generative disorders: a functional imaging approach. Trends Neurosci. 2009;32:548-557, Copyright 2009, with permis‐
sion from Elsevier).
5. Parkisonian tremor and metabolic changes
5.1. Parkinsonian tremor
A resting tremor of 3–6 Hz is one of the cardinal features of PD that presents in 75 to 100% of
patients during the course of the illness [36, 37]. The parkinsonian tremor is typically asym‐
metrical, at least initially, and it affects the upper limbs before involving the ipsilateral leg after
about 2 years. Tremor of the lips, jaw, or tongue may also occur. Head or voice tremor is rare,
which contrasts with observations of essential tremors. A postural tremor is also present in
most cases, and it exhibits a wide range of severity [38]. However, kinetic tremor is uncom‐
mon [39]. An isolated lower-leg resting tremor is an uncommon symptom of neurological
disease and an unusual presentation of PD, and such tremors are typically suspected to be
caused by multiple system atrophy, psychogenic tremor, or drug-induced parkinsonism [40].
The pathophysiology of parkinsonian tremors is thought to be distinct from that of akinesia
and rigidity [2, 3]. The clinical progression and mental status declines of patients with akinetic-
rigidity-dominant PD are more rapid compared to patients with tremor-dominant PD [41].
Moreover, the loss of DAergic projections to the striatum correlates with the clinical ratings of
bradykinesia and rigidity, but not with those of tremor [5, 42]. Indeed, DAergic therapy is less
effective on parkinsonian tremor than it is on akinesia and rigidity.
The Vim nucleus of the thalamus has commonly been recognized as the optimal surgical target
for the treatment of tremors. Neurons in this region receive projections from the deep cerebellar
nuclei and discharge in synchrony with parkinsonian tremors [43]. Given that PD tremors can
be modulated by the lesioning of other brain regions, such as the pons and cerebellum, the
Vim nucleus is considered one of a number of interconnected nodes in a spatially distribut‐
ed tremor circuit. Nevertheless, the precise anatomical and functional network underlying
tremors is still unclear, particularly with respect to the relative contributions of the basal
ganglia and cerebellum to this pathway [3, 44–47].
5.2. The PDTP
In order to identify the PDTP, FDG-PET scans were acquired in patients with tremor-predom‐
inant PD who underwent Vim-DBS. The PDTP was identified with an ordinal trends/canoni‐
cal variates analysis, which is a within-subject network-mapping algorithm that is based on
PCA methods [48], by comparing scans that were conducted during Vim-DBS OFF (i.e., tremor
present) and Vim-DBS ON (i.e., tremor suppressed) [7]. This pattern is characterized by
increased activity in the cerebellum and dorsal pons, primary motor cortex, and caudate and
putamen (Figure 3a). Unlike PDRP, prospectively computed PDTP correlates with acceler‐
ometer measurements of the tremors and UPDRS tremor subscale scores, but not with UPDRS
bradykinesia-rigidity subscale ratings (Figure 3b and 3c). Interestingly, Vim-DBS was
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associated with changes in PDTP expression, but not PDRP expression. Although STN DBS
decreased the activity in both networks, PDTP expression was reduced more by Vim than by
STN stimulation (Figure 4). Moreover, while both the PDRP and the PDTP progressed over
time, the rate of the PDTP increase was much slower than that of the PDRP. These findings
suggest major differences between the tremor- and bradykinesia/rigidity-related brain
networks in terms of their clinical correlates, treatment effects, and natural histories. The
bradykinetic manifestations of PD have been associated with discrete functional abnormali‐
ties of the CSPTC pathways [49]. In contrast, tremor generation has been linked to abnormal
activity in cerebello-thalamo-cortical pathways [44, 46, 47], and the role of the basal ganglia in
the etiology of this symptom is still controversial [46, 50]. Indeed, prior H215O PET imaging
studies have shown that both the lesioning and the stimulation of the thalamic Vim nucleus
results in localized reductions in neural activity in the primary motor cortex and anterior
cerebellum [51, 52]. Moreover, a magnetoencephalography study revealed a tremor-coher‐
ent oscillatory network involving the primary motor cortex, thalamus, and cerebellum [47].
These findings give support to the suggestions that PDTP topography and the cerebello-
thalamo-cortical circuit are associated with parkinsonian tremors. Interestingly, the PDTP
topography includes a significant contribution from the striatum, although the contribution is
less than those of the other nodes of this network. In the primate, the striatum receives
cerebellar output through the ventrolateral and intralaminar thalamic nuclei [53]. In aggre‐
gate, the regional nodes of the PD tremor network may be defined by the abnormal synchro‐
nization of firing, which results in localized increases in synaptic activity and concomitant
increases in glucose metabolism. While the tremor-related metabolic changes that are observed
are most prominent in the primary motor cortex and thalamus, these PDTP regions intercon‐
nect through the thalamic Vim nucleus and putamen [7].
Figure 3. Neuroimaging analysis on Parkinson’s disease tremor-related pattern. (a) PD tremor-related pattern
(PDTP). This spatial covariance pattern was identified by an ordinal trends/canonical variate analysis of the FDG-PET
data from nine patients with tremor-dominant PD who were scanned when they were on and off ventral intermediate
nucleus (Vim) stimulation. The pattern is characterized by hypermetabolism in the primary motor cortex, anterior cer‐
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ebellum/dorsal pons, and putamen. (b) PDTP expression correlated with the UPDRS subscale ratings for tremor in 40
patients with PD (r = 0.54, p < 0.001). (c) The correlation of the PDTP scores with tremor was significantly greater in
magnitude than that with the subscale ratings for akinesia-rigidity (p < 0.01; multiple regression analysis). (From Mure
H. et. al., Parkinson’s disease tremor-related metabolic network: characterization, progression, and treatment effects.
Neuroimage. 2011;54:1244-1253 Copyright 2011, with permission from Elsevier).
Figure 4. Changed activity of the metabolic network as a result of deep brain stimulation (DBS) for parkinsonian
tremor. (a) Bar graphs showing the mean baseline PDTP expression (±SE) in patients who were treated with Vim-DBS
(black), patients who were treated with subthalamic nucleus (STN) DBS (gray), and healthy control subjects (white).
PDTP expression differed significantly across the three groups (p < 0.001; one-way ANOVA), with comparable increas‐
es in the baseline expression in both the Vim-DBS (p < 0.005) and STN DBS (p < 0.001) groups relative to the controls.
(b) The baseline PDRP expression also differed across the three groups (p < 0.001), with higher expression in both treat‐
ment groups relative to the controls (p < 0.001). Nonetheless, PDRP expression was higher in the STN DBS group than
in the Vim-DBS group (p < 0.01). (c) Treatment-mediated changes (ON-OFF) in PDTP expression (±SE) in the Vim-DBS
patients (black), STN DBS patients (gray), and test-retest PD control subjects (white). The changes in PDTP expression
differed across the three groups (p < 0.001; one-way ANOVA), with stimulation-mediated declines in network activity
in both DBS groups (Vim: p < 0.001; STN: p = 0.01, relative to the test-retest control group). The PDTP changes were
greater as a result of Vim stimulation compared with STN stimulation (p < 0.05). (d) There was also a significant group
difference in the treatment-mediated PDRP changes (p = 0.02). The treatment-mediated reductions in PDRP expression
were significant (p < 0.05) after STN stimulation, but not after Vim stimulation (p = 0.16). (From Mure H. et. al., Parkin‐
son’s disease tremor-related metabolic network: characterization, progression, and treatment effects. Neuroimage.
2011;54:1244-1253 Copyright 2011, with permission from Elsevier).




Neuroimaging study with the new multivariate network analysis is now used to elucidate the
disease-related network abnormalities that involve the functional changes of certain brain
regions in multiple neurodegenerative diseases. Particularly in PD, it has contributed to our
understanding of the pathophysiology of the nigrostriatal dopaminergic system and of the
non-dopaminergic system. Quantification of PD-related metabolic pattern could improve the
accuracy and precision in diagnosing PD. Moreover, it also could provide an objective means
of assessment of the PD therapies such as DBS.
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